Clinical Edge Journal Scan

DNA-based model predicts overall survival in breast cancer


 

Key clinical point : A prognostic signature including 8 DNA repair-related genes (MDC1, RPA3, MED17, DDB2, SFPQ, XRCC4, CYP19A1, and PARP3) predicted overall survival in breast cancer patients

Major finding : The areas under the curve were for 3-year survival and 5-year survival were 0.717 and 0.772, respectively, in the GSE9893 data set, and 0.691 and 0.718, respectively, in the GSE42568 data set.

Study details : The data come from 1,096 women with breast cancer; gene expression profiles and clinical data were collected from a Chinese health database between October 9, 2019, and February 3, 2020.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Citation: Zhang D et al. JAMA Netw Open. 2020 Oct 5. doi:10.1001/jamanetworkopen.2020.14622.

Recommended Reading

Study supports genetic testing in older women with breast cancer
MDedge Hematology and Oncology
New cancer drugs may have saved more than 1.2 million Americans
MDedge Hematology and Oncology
‘Test all patients with cancer’: One in eight have inherited mutations
MDedge Hematology and Oncology
Pembrolizumab approved for triple-negative breast cancer
MDedge Hematology and Oncology
Using telehealth to deliver palliative care to cancer patients
MDedge Hematology and Oncology
Pregnancy outcomes ‘favorable’ after BRCA breast cancer treatment
MDedge Hematology and Oncology
Black women show higher rates of three breast cancer subtypes
MDedge Hematology and Oncology
Immediate breast reconstruction after chemotherapy doesn’t hurt survival
MDedge Hematology and Oncology
Vacuum-assisted biopsy predicts post-treatment residual disease in breast cancer
MDedge Hematology and Oncology
Textured breast implants may raise risk of cancer relapse
MDedge Hematology and Oncology